Company Description
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies.
It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development.
The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production.
The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019.
Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2002 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Raymond Vennare |
Contact Details
Address: 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 United States | |
| Phone | (412) 432-1500 |
| Website | predictive-oncology.com |
Stock Details
| Ticker Symbol | POAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446159 |
| CUSIP Number | 74039M200 |
| ISIN Number | US74039M3097 |
| Employer ID | 33-1007393 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Raymond F. Vennare | Chief Executive Officer and Chairman |
| Joshua Blacher M.B.A. | Interim Chief Financial Officer |
| Theresa Ferguson | Senior Director of Marketing |
| Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Senior Vice President of Biologics |
| Dr. Arlette H. Uihlein FCAP, M.D. | Senior Vice President of Translational Medicine and Drug Discovery and Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Sep 20, 2024 | 8-K | Current Report |
| Aug 23, 2024 | EFFECT | Notice of Effectiveness |
| Aug 21, 2024 | UPLOAD | Filing |
| Aug 15, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 29, 2024 | 8-K | Current Report |